drugset / Trial / NCT02609490

Azilsartan in Chinese Patients With Mild and Moderate Hypertension

NCT02609490

Phase 3 Completed 304 enrolled Lee's Pharmaceutical Limited
RandomizedParallel-groupTriple-blindTreatment

Summary

A phase 3 clinical study to evaluate the safety and efficacy of Azilsartan in Chinese hypertension patients

Timeline

Start
2015-09
Primary completion
2017-02
Completion
2018-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Azilsartan Unknown 20 mg
Comparator Olmesartan medoxomil Unknown 20 mg